Catalent, Inc. (CTLT)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 59.69 |
| Open | 59.51 |
| Bid | 59.04 x 800 |
| Ask | 60.47 x 800 |
| Day's range | 59.60 - 59.79 |
| 52-week range | 31.80 - 61.20 |
| Volume | |
| Avg. volume | 1,831,437 |
| Market cap | 10.819B |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.76 |
| Earnings date | 13 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 60.75 |
ZacksCatalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GuruFocus.comDecoding Catalent Inc (CTLT): A Strategic SWOT Insight
Unveiling the Financial and Strategic Dynamics of Catalent Inc's Market Position
ReutersCatalent delays filing of annual report
The contract drug manufacturer was expected to file the report on Aug. 29. The company is awaiting the closing of the $16.5 billion takeover deal signed in February by Novo Holdings, the investment firm that has a controlling interest in Danish drugmaker Novo Nordisk. Catalent expects the deal to close towards the end of the year.
© 2024 Yahoo. All rights reserved.